FDA Issues Safety Communication for BioZorb Markers and Potential Risks with Use in Breast Tissue
Jinks Crow
Feb 28, 2024
1 min read
Updated: May 9, 2024
As a result of the ongoing litigation by Jinks Crow, the FDA has issued a safety communication regarding Biozorb® markers and potential risks with use in breast tissue.
If you or a loved one was implanted with a Biozorb® device as part of treatment for breast cancer and has experienced any of the above injuries, please contact Jinks Crow & Dickson for a free consultation with an attorney.
Comments